Skip to main content

Leuprolide Acetate Use Among Patients with Central Precocious Puberty

Basic Details
Date Posted
Status
Complete
Medical Product
leuprolide acetate
Health Outcome(s)
central precocious puberty
Description

The goal of this request was to characterize central precocious puberty (CPP) diagnoses and leuprolide acetate dispensing in the Sentinel Distributed Database (SDD). This request contains two reports. Report 1 examines the distribution of time between patients' first new diagnosis and leuprolide acetate dispensing. Report 2 contains counts of individuals with well child visits in the SDD.

Data from January 1, 2000 to October 31, 2017 from 17 Data Partners contributing to the SDD were included in this report. This request was distributed to Data Partners on March 29, 2018.

Deliverables (2)
Sentinel Modular Program Report: Leuprolide Acetate Use Among Patients with Central Precocious Puberty, Report 1 Sentinel Modular Program Report: Leuprolide Acetate Use Among Patients with Central Precocious Puberty, Report 2
Additional Details
FDA Center
CDER
Time Period
January 1, 2000 - October 31, 2017
Analysis Type
Descriptive
Population / Cohort
Individuals 18 years of age and younger
Data Sources
Sentinel Distributed Database (SDD)
Related Links
Sentinel Drug Study: Leuprolide Acetate & Major Fracture, Any Fracture, Hip Replacement, and Temporomandibular Joint Replacement